You are using an older browser version. Please use a supported version for the best MSN experience.

CURIS, INC.

NASDAQ: CRIS
1.13
+0.01
+0.89%

Sector

Healthcare

Industry

Biotechnology & Medical Research

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Key People

James E. Dentzer

President, Chief Executive Officer, Director

Robert E. Martell

Head - Research and Development

Lori A. Kunkel

Independent Director

Martyn D. Greenacre

Independent Chairman of the Board

Marc Rubin

Independent Director

  • Curis Inc

  • 128 SPRING STREET, BUILDING C, SUITE 500

  • LEXINGTON, MA 02421

  • US.Map

  • Phone: +1 617 5036500

  • Fax: +1 617 5036501

  • curis.com

Incorporated

2000

Employees

28

Insider Trades
  • Recent
  • All
  • Date

  • Name

  • Transaction

  • Shares

  • Price(s)

  • Value

    • 1/23/2020

    • DENTZER JAMES E

    • Sold

    • 6,752

    • 1.69

    • 11,410.20

    • Date

    • Name

    • Transaction

    • Shares

    • Price(s)

    • Value

      • 1/23/2020

      • DENTZER JAMES E

      • Sold

      • 6,752

      • 1.69

      • 11,410.20

      AdChoices
      AdChoices
      AdChoices
      image beaconimage beaconimage beacon